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Abstract
The low-affinity IgE receptor FceRII (CD23) is part of the regulatory system
controlling IgE synthesis in human B cells and exists in membrane and soluble
forms. Binding of IgE to CD23 has been described to have stabilizing effects and to
prevent cleavage of CD23. Previous experiments using anti-CD23 antibodies
reduced IgE synthesis but were difficult to interpret as the antibody Fc part might
alsomediate feedbackmechanisms. The purpose of this study was to investigate the
regulatory role of CD23, by using designed ankyrin repeat proteins (DARPins) that
specifically recognize CD23. Anti-CD23 DARPins were isolated by ribosome
display and were produced as monovalent and bivalent constructs. Affinities to
CD23 were measured by surface plasmon resonance. IgE synthesis and up-
regulation of CD23 in human peripheral B cells were induced by IL-4 and anti-
CD40 antibody. We assessed CD23 expression and its stabilization by FACS and
used an ELISA for detecting soluble CD23. IgE synthesis was measured by ELISA
and real-time PCR. Surface plasmon resonance revealed affinities of the DARPins
to CD23 in the pico-molar range. Anti-CD23 DARPins strongly inhibited binding
of IgE to CD23 and share thus a similar binding epitope as IgE. The DARPins
stabilized membrane CD23 and reduced IgE synthesis in an isotype specific
manner. Furthermore, the anti-CD23 DARPins decreased IgE transcript through
inhibition of mature Ce RNA synthesis suggesting a posttranscriptional control
mechanism. This study demonstrates that targeting CD23 alone is sufficient to
inhibit IgE synthesis and suggests that a negative signaling occurs directly through
the CD23 molecule.
Introduction
FceRII (CD23) is the low affinity receptor for IgE. It is a type II
transmembrane glycoprotein consisting of a short cyto-
plasmic N-terminus followed by an extracellular part with a
stalk region and a C-type lectin-domain at the C-terminus,
where binding of IgE occurs [1]. CD23 appears in a trimeric
form due to an a-helical coiled-coil structure in the stalk
region leading to enhanced binding of IgE (KD 3.7 108M)
through an avidity effect [2, 3].
In B cells, alternative splicing results in the expression of
CD23 in two isoforms (CD23a and CD23b) differing in six
or seven amino acids at the N-terminus [1]. CD23a is
constitutively expressed in B cells while CD23b, expressed
upon stimulation with IL-4, is present also on monocytes,
follicular dendritic cells as well as intestinal epithelial
cells [1, 4]. Both isoforms were described to have different
functions. CD23a on B cells is thought to be associated
with endocytosis of IgE-allergen complexes, whereas
CD23b with IgE-mediated phagocytosis [5, 6]. Moreover,
CD23 also exists in a soluble form which is derived from
the cell-bound form by cleavage through specific pro-
teases [7]. Previous studies have reported that soluble
CD23 positively controls IgE synthesis by cross-linking
membrane IgE with CD21 [8]. It has been hypothesized
that binding of IgE or anti-CD23 antibodies to the lectin
domain renders CD23 less susceptible to cleavage by
proteases leading to a reduced IgE synthesis. Furthermore,
specific inhibition of the protease ADAM 10 has
demonstrated a reduction in the synthesis of IgE [8–11].
These data suggest that surface CD23 may be involved in a
negative feedback inhibition of IgE synthesis.
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Themonoclonal chimeric anti-CD23 antibody, lumiliximab
(Biogen Idec, Cambridge,Massachusetts) was shown to reduce
IL-4-induced IgE synthesis in vitro [12]. Furthermore,
lumiliximab was demonstrated to reduce serum IgE levels in
allergic patients [13] and to mediate apoptosis and anti-tumor
activity in chronic lymphocytic leukemia cells [14]. This
provides proof of principle that CD23 is a valid target to down-
regulate B cell activation. Previous studies have demonstrated
that binding of CD23 by IgE/anti-IgE immune-complexes or
anti-CD23 antibodies on a human IgE-secreting B cell line
suppresses IgE synthesis [15]. These experiments provide
evidence that cross-linking of CD23 is crucial for the inhibition
of IgE synthesis, as no inhibition was observed using
monomeric IgE [11, 15]. Nevertheless, it remains unknown
whether targetingCD23 is sufficient to reduce IgE synthesis as it
has been claimed that inhibition of IgE synthesis by anti-CD23
monoclonal antibodies is Fc-mediated through cross-linkingof
CD23 with the inhibitory FcgRIIb [16].
To investigate the effects of targeting CD23 in more detail
we have used non-immunoglobulin-like binding scaffolds
termed designed ankyrin repeat proteins (DARPin) lacking
an Fc-domain. DARPin binders with high specificities and
high affinities have been already isolated against various
targets [17, 18]. DARPins are expressed in high quantities
and in soluble form in Escherichia coli; moreover they can be
easily fused to each other [19] or to other molecules [20] to
generate bispecific binding molecules. Two DARPins were
isolated and produced as monovalent and bispecific
proteins, both recognizing specifically CD23. These DAR-
Pins were able to compete with IgE for binding of CD23 and
were tested for their ability to stabilize CD23 and to inhibit
IgE synthesis in human B cells.
Materials and Methods
Isolation of human B cells
Buffy coats were purchased from the blood donation center
(Bern, Switzerland). The studywas approved by the local ethics
committee. Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation on Ficoll Paque (GE
Healthcare, Chalfont St. Giles, UK). B cells were isolated by
negative selection using magnetic beads (StemCell Technolo-
gies, Grenoble, France). The average purity of B cells from five
independent donors was 94% 0.8 (n¼ 5) as determined by
flow cytometry (Supplementary Fig. S4A).
In vitro selection and production of monovalent
and bivalent DARPins
The principle of DARPin selection is published else-
where [21]. DARPin libraries were screened by ribosome
display to select specific binders against the extracellular part
of recombinant CD23 (R&D, Minneapolis, Minnesota) as
described previously [19]. Briefly, after four selection
rounds, binders were produced in E. coli. Crude DARPin
extracts were screened by ELISA to identify specific binders
against CD23 which led to the selection of two specific
DARPins. Bivalent and bispecific DARPins were produced
using the plasmid pQi-bi-2-2 (kindly provided byMolecular
Partners AG, Schlieren, Switzerland). Expression and
purification of monovalent, bivalent, and bispecific DAR-
Pins was performed as published [19]. Additionally, the
DARPins were applied to a Superdex 75 column for a size
exclusion chromatography (HiLoad 26/60Sudex75, €Akta,
Uppsala, Sweden). Plasmid DNA frommonovalent, bivalent
and bispecific DARPins were sequenced at Microsynth
(Balgach, Switzerland).
Cell culture
B cells were cultured in 48-well plates at 2 106 cells/mL in
RPMI 1640 (Gibco, Grand Island, New York) containing
10% FBS (Thermo Scientific, Cramlington, UK), Transferrin
40mg/mL (Calbiochem, Darmstadt, Germany), mercaptoe-
thanol 50mM (Sigma–Aldrich, St. Louis, Missouri), Sodium
pyruvate 1mM (Sigma–Aldrich), bovine insulin 4mg/ml
(Sigma–Aldrich), L-glutamine 2mM (Gibco), and MEM
Non-essential amino acids 1:100 (Gibco). Cells were
activated with IL-4 20 ng/mL (Peprotech, Rocky Hill, New
Jersey) and anti-CD40 antibody 1mg/mL (eBioscience, San
Diego, California) for up to 13 days. RPMI 8866 cell line was
cultured in RPMI 1640 medium (Biochrom, Berlin,
Germany) supplemented with 10% FBS. Anti-CD23 DAR-
Pins were added to the cell culture at day 0 at a concentration
of 300 nM if not otherwise stated.
Surface plasmon resonance
Affinities of DARPins were measured on a Biacore X100
instrument (GE Healthcare) with HBS-EPþ running buffer
(GE Healthcare). Recombinant CD23 (Uniprot P06734,
amino acids 48-321) was immobilized on a CM5 biosensor
chip using a standard amine coupling kit (GE Healthcare) to
an immobilization level of 2400 response units (RU).
Binding of anti-CD23 DARPins was assessed in a twofold
serial dilution with at least ten concentrations. Samples were
injected for 2min, followed by 10min dissociation. Kinetic
parameters were calculated with BIAevaluation software (GE
Healthcare) using global fitting of the binding data with a 1:1
Langmuir binding.
Flow cytometry
To visualize CD23, CD20, and CD45 on B cells, cells
were stained using Phycoerythrin(PE)-conjugated mouse
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anti-human CD23 IgG1 1:500 (R&D) or with PerCP-
conjugated mouse anti-human CD20 IgG2b 1:500 (Biol-
egend, San Diego, California) or with FITC-conjugated
mouse anti-human CD45 1:500 (Miltenyi Biotec., Bergisch
Gladbach, Germany) for 30min at 48C, washed and analyzed
on guava easyCyteTM Flow cytometer (Merck Millipore,
Darmstadt, Germany). In the inhibition assays, the chimeric
IgE-JW8 [22] was FITC-labeled using LYNX Rapid
Fluorescein antibody conjugation kit (Bio-RAD, Kidlington,
UK). Cell viability was assessed using annexin V-APC
(Biolegend) and 7-AAD (Biolegend). Data were analyzed
using FLOWJO software (TreeStar Inc., Ashland, Oregon).
ELISA
Ninety six-well microtiter plates (Costar, Cambridge,
Massachusetts) were coated with monoclonal mouse
anti-human IgE HB235 at 5mg/mL (ATCC, Manassas,
Virgina), polyclonal sheep anti-human IgG at 5mg/mL
(Binding Site, Birmingham, UK), with sheep anti-human
IgG1 1:1000 (Binding Site), with sheep anti-human IgG4
1:1000 (Binding Site), with sheep anti-human IgM 1:1000
(Binding Site), or with monoclonal mouse anti-human
CD23 at 2mg/mL (R&D) overnight in PBS. Unspecific
binding sites were blocked with PBS-casein (0.15%) for 2 h
at 378C. Cell culture supernatants were incubated for 3 h at
378C. Detection antibodies were the following: horseradish
peroxidase HRP-conjugated sheep anti-human IgE 1:1000
(Binding Site), HRP-conjugated sheep anti-human IgG
1:2000 (Binding Site), HRP-conjugated sheep anti-human
IgM 1:1000 (Binding Site) and HRP-conjugated goat anti-
human CD23 1:500 (R&D). TMB (3,30,5,50-tetramethyl-
benzidine) was used as substrate and was stopped with 1M
sulphuric acid. Monoclonal human IgE (Sus11) [23],
humanized monoclonal IgG omalizumab IgG1 (Xolair1,
Novartis, Switzerland) or recombinant human CD23
(Uniprot P06734, amino acids 48-321) were used for
standard curves and concentrations were interpolated
(nonlinear regression) using Prism 6.0 software (Graph-
Pad, San Diego, California).
Real-time PCR
Total mRNA was isolated using Guanidinum thiocyanate-
phenol-chloroform extraction (TRI Reagent, MRC, Cin-
cinnati, Ohio). Isolated mRNA was reverse transcribed
using random hexamer primers (Applied Biosystems,
Branchburg, New Jersey) and Superscript II (Life Technol-
ogies, Gaithersburg, Maryland). qPCR was performed
using TaqMan Universal Master Mix (Applied Biosystems)
on a 7500 Real Time System (Applied Biosystems).
Expression was normalized to the endogenous control
b2-microglobulin and relative expression was determined
on 7500 system software (Applied Biosystems). Following
primers and probes were used: b2-microglobulin,
Hs00187842_m1; IgG1, Hs00378340_m1 (Applied Bio-
systems). IgG4 forward: 50-CTGGTCACCGTCTCCTCA-
30, reverse: 50-AGTAGTCCTTGACCAGGCA-30, probe:
50-FAM-TTCAAGGGCCCATCGGTCTTCC-tamra-30; IgE
forward (mature): 50-ACCCTGGTCACCGTCTCC-30, for-
ward (germline): 50-ACCATCCACAGGCACCAA-30, reverse:
50-GAGTCACGGAGGTGGCATT-30, probe: 50-FAM-
CCCTTGACCCGCTGCTGCAAA-tamra-30; CD23a forward:
50-TGGAGGAAGGTCAATATTCAGAG-30, CD23b forward:
50-ATGAATCCTCCAAGCCAGGA-30, reverse: 50-GCCACAG-
GAGAAGCAGAGTC-30, probe: 50-FAM-GGTGTTGCAGGCG
TGGGACT-tamra-30 were ordered at Microsynth (Balgach,
Switzerland).
Results
Selection of DARPins specific for CD23
Binders recognizing recombinant CD23 were isolated from
two DARPin libraries coding for either two (N2C) or three
(N3C) randomized ankyrin repeat modules. Binders were
expressed and crude DARPin extracts were screened for
specificity in an ELISA. Two N3C DARPins termed D86 and
D89, displaying no reactivity to control proteins, were
chosen for further investigation and expressed in E. coli as
monovalent (D86, D89) and bivalent (D86-86, D89-89)
proteins.
In order to investigate whether the twoDARPinmolecules
D86 and D89 recognize different epitopes on CD23, we
performed an assay on surface plasmon resonance. The chip
surface was coated with bivalent DARPin D86-86 (Supple-
mentary Fig. S1) and subsequently incubated with recombi-
nant CD23 until the sensogram reached a stable response.
DARPin D89 was then injected and was still able to bind to
CD23 indicating that the two DARPins, D86 and D89,
recognize different epitopes on CD23 which is a prerequisite
to generate bispecific DARPins. Monovalent DARPins D89
and D86 were then fused and expressed as a bispecific
DARPin (D89-86). SDS-PAGE showed that DARPins D86,
D86-86 and D89-86 run as monomeric molecules, while
DARPins D89 and D89-89 tend to form dimers (Supple-
mentary Fig. S2).
Determination of kinetic parameters of anti-CD23
DARPins
Kinetic parameters of anti-CD23 DARPins were assessed by
surface plasmon resonance on immobilized CD23 (Supple-
mentary Fig. S3 and Table 1). Monovalent DARPins showed
similar association and dissociation rates, resulting in low
micromolar equilibrium dissociation constants (Table 1).
M. Fellmann et al. High affinity targeting of CD23
© 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 341
Compared to monovalent DARPins, bivalent D86-86 and
bispecific D89-86 DARPins had an almost unaltered on-rate
but a lower off-rate resulting in increased KD values of nearly
four orders of magnitude. These improved affinities might
be mainly due to increased avidity. Interestingly, bivalent
DARPin D89-89 has a faster off-rate, which results in an
affinity ten times less compared with the other bivalent and
bispecific molecules.
Inhibition of IgE binding to membrane CD23 by
anti-CD23 DARPins
To assess the capacity of the anti-CD23 DARPins to block
binding of IgE to CD23, an inhibition assay was
performed using the lymphoblastoid B cell line RPMI
8866. From the affinity experiment, there was evidence
that the bispecific and bivalent DARPins (D89-86,
D86-86) had the highest affinities. Therefore, the experi-
ment was performed by mixing monovalent (D86, D89),
bivalent (D86-86), and bispecific (D89-86) DARPins at
different concentrations with a saturating concentration
(25 nM) of FITC-labeled IgE before adding to the cells. As
shown in Figure 1, both monovalent DARPins D86 and
D89 inhibited the interaction of IgE with CD23 to more
than 80% only at the highest concentration. Compared to
the monovalent DARPins, bispecific DARPin D89-86
showed an inhibition of more than 80% already at the
lowest concentration (0.4 nM). Surprisingly, the inhibito-
ry capacity of bivalent DARPin D86-86 was not better
than that of the monovalent DARPins. This might
indicate a steric hindrance of the bivalent DARPin in
binding to membrane CD23. The binding of IgE to CD23
was not inhibited by non-specific bivalent (nsD-D) and
monovalent (nsD) control DARPins (Fig. 1). These results
showed that the bispecific DARPin (D89-86) performed as
the most potent inhibitor and was chosen for subsequent
in vitro cell assays.
Anti-CD23 DARPins stabilize membrane CD23
As targeting CD23 by IgE has been shown to stabilize surface
CD23 [24, 25], we investigated whether the bispecific
DARPin D89-86 displays the same effect on primary human
B cells isolated from peripheral blood. B cells were
stimulated with IL-4 plus anti-CD40 antibody in order to
induce class-switch toward IgE synthesis as well as to up-
regulate expression of CD23. Initial expression of CD23 was
detected in 10–20% of isolated B cells at day 0 and was
increased to 70–80% already after 24 h of stimulation where
it remained constant for the following 13 days (Fig. 2A and
B). In the presence of DARPin D89-86, the amount of CD23
positive cells was significantly enhanced during the time
course of the experiment compared to control samples
(Fig. 2B and C). Furthermore, when added at different
concentrations at the onset of the experiment, the effect of
D89-86 on stabilization was found to be dose dependent
(Supplementary Fig. S5E). To obtain more evidence for the
effect of DARPin D89-86 on the expression of surface CD23,
we purified B cells from at least five donors and compared
the effect of D89-86 with its monovalent analogs after 6 and
after 13 days of culture. The expression of CD23 was
normalized to IL-4/anti-CD40-stimulated samples. No
difference in the expression of CD23 was observed with
monovalent DARPins D86 andD89 at day 6 (Supplementary
Fig. S5A) and at day 13 (Fig. 2D). In contrast, with the
bispecific DARPin D89-86, a significant increase in CD23
expression was found after 6 (Supplementary Fig. S5B) and
13 days (Fig. 2E).
As expected, supernatants of IL-4/anti-CD40-stimulated
B cells showed an increase of soluble CD23 in comparison
with unstimulated samples. Monovalent DARPins D89 and
D86 as well as bispecific DARPin D89-86 significantly
decreased the amount of soluble CD23 after 6 (Supplemen-
tary Fig. S5C and D) and 13 (Fig. 2F and G) days of culture.
Table 1. Binding afﬁnities of anti-CD23 DARPins for human CD23.
Name Structure ka [M
1 s1] Kd [s
1] KD [M]
D86 1.28 107 3.69 101 2.88 108
D89 2.95 107 4.53 101 1.54 108
D86-86 5.79 107 1.54 104 2.66 1012
D89-89 6.99 108 8.94 103 1.28 1011
D89-86 2.79 107 4.46 105 1.60 1012
Figure 1. Flow cytometry analysis showing the inhibition of IgE binding
to CD23 by anti-CD23 DARPins. Anti-CD23 monovalent (D89, D86),
bivalent (D86-86), and bispeciﬁc (D89-86) DARPins at different concen-
trationsweremixedwith FITC-labeled IgE at a saturating concentration of
25 nM and were added to RPMI 8866 cells for 30min at 48C. Two
unspeciﬁc monovalent (nsD) and bivalent (nsD-D) DARPins were used as
controls. The results are expressed in percentage of IgE binding to CD23.
High affinity targeting of CD23 M. Fellmann et al.
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Figure 2. Anti-CD23 DARPins stabilize membrane CD23 on human B cells. (A) Surface CD23 of puriﬁed human B cells was stained before (Day 0) and
after overnight (Day 1) incubationwith andwithout IL-4 and anti-CD40 antibody. (B) Time course of surface CD23 expression in human B cells cultured in
medium or IL-4 and anti-CD40 with or without the bispeciﬁc anti-CD23 DARPin (D89-86) or the bispeciﬁc control DARPin (nsD-D) added at day 0. The
cells were stained with PE-labelled anti-CD23 antibody and analysed by ﬂow cytometry. The results are expressed as percent CD23 positive cells.
(C) Representative histogram from one donor after stimulation with D89-86 in comparison with IL-4/anti-CD40 stimulation alone. The cells were stained
at day 13 with PE-labeled anti-CD23 antibody. (D, E) Surface level of CD23 on puriﬁed human B cells cultured in the presence the anti-CD23 DARPins or
with the non-speciﬁc control DARPins (nsD and nsD-D) assessed at day 13. The results are expressed as normalized geometricmean ﬂuorescence intensity
(gMFI) relative to cells treated with IL-4 and anti-CD40 antibody alone. (F, G) Puriﬁed human B cells were cultivated with IL-4 and anti-CD40 alone or in
the presence of the anti-CD23 DARPins D86, D89 or D89-86 added at day 0. No effects were observed using the non-speciﬁc control DARPins (nsD and
nsD-D). Cell supernatants were collected at day 13 and soluble CD23 levels were measured by ELISA. Each point represents an individual donor. Shown
are means SEM, statistical signiﬁcance was calculated using 1-way ANOVAwith Dunnet's post-comparison test and considered signiﬁcant if P< 0.05.
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However, the reduction was more pronounced with
bispecific DARPin D89-86. For comparison, the control
DARPins (nsD and nsD-D) did neither influence the
expression of membrane CD23, nor the amount of
soluble CD23 released into the supernatants. Altogether,
these findings indicate that anti-CD23 DARPins stabilize
surface CD23 and confirm the relationship between
stabilization and the release of soluble CD23.
Influence of anti-CD23 DARPins on CD23 mRNA
expression
Next, we investigated whether the stabilized CD23 expres-
sion induced by DARPin D89-86 in IL-4/anti-CD40-
stimulated B cells influences CD23 mRNA. Although B cells
show a constitutive expression of isoform a, both isoforms
are up-regulated by IL-4 (data not shown). Incubation of B
cells with bispecific DARPin D89-86 did not significantly
influence expression of CD23 mRNA, indicating a post-
transcriptional mechanism of membrane CD23 stabilization
(Fig. 3A and B).
Anti-CD23 DARPins reduce IgE synthesis in human
B cells in an isotype-specific manner
Having demonstrated stabilization of membrane CD23 by
targeting CD23, we investigated the effect of anti-CD23
DARPins on IgE synthesis in B cells after 13 days of
IL-4/anti-CD40 stimulation. A significant inhibition of IgE
synthesis was observed when B cells were incubated with
bispecific DARPin D89-86 (Fig. 4B). In contrast, only a
minimal reduction of IgE synthesis was observed with
monovalent DARPins D86 and D89 that did not reach
statistical significance (Fig. 4A). To investigate whether
bispecific DARPin D89-86 influences the level of transcrip-
tion, we examined the germline CemRNA transcript (eGLT)
and mature mRNA production by real-time qPCR at day 6.
Figure 4C shows that the expression of the mature transcript
was significantly reduced with bispecific DARPin D89-86,
thereby confirming the observed reduction of IgE synthesis.
However, eGLT was not reduced after 6 days (Fig. 4C). As
eGLT can be detected earlier, we analyzed its expression after
3 days but DARPin D89-86 showed no inhibitory effect on
eGLT (data not shown).
In order to assess the effect of DARPins on other Ig
isotypes, we measured total IgG, IgG1, IgG4, and IgM
synthesis in IL-4/anti-CD40-stimulated B cells after 13 days.
No significant reduction in the synthesis of these isotypes
was observed with either monovalent D86 or D89 (Fig. 4D)
or with bispecific D89-86 (Fig. 4E and Supplementary
Fig. S6A–C) DARPins. We further assessed IgG1 and IgG4
mRNA transcripts at day 6 to investigate potential effects of
D89-86 at the level of mRNA transcription. As peripheral B
cells might contain already switched B cells producing IgG,
human peripheral na€ve B cells were isolated and stimulated
with IL-4 plus anti-CD40. Indeed, no reduction of either
IgG1 or IgG4 mRNA expression was observed upon
stimulation with bispecific DARPin D89-86 (Fig. 4F)
indicating that the effect of the bispecific DARPin on IgE
synthesis was isotype-specific.
Anti-CD23 DARPins do not induce cell death in
human B cells
It has been previously demonstrated that the anti-CD23
antibody, lumiliximab, can induce apoptosis in chronic
lymphocytic leukemic cells [14]. Therefore, we hypothe-
sized that inhibition of IgE synthesis could be due to the
induction of apoptosis. To determine whether DARPin
D89-86 induces apoptosis, B cells were incubated with IL-4
plus anti-CD40 in the presence and absence of DARPin
D86-89 and the control DARPin (nsD-D). After 6 days
Figure 3. Effect of the bispeciﬁc anti-CD23 DARPin D89-86) on CD23 mRNA transcription. Human B cells were cultured with IL-4 and anti-CD40 alone
or in the presence of the bispeciﬁc anti-CD23 DARPin or bispeciﬁc control DARPin (nsD-D) added at day 0. Expression of CD23a (A) and CD23b (B) mRNA
was quantiﬁed by real time RT-PCR after 1, 3, and 6 days. Relative expression is shown as fold change compared to anti-CD40/IL-4-stimulated samples
(DDCt). Bars represent means SEM of at least three different donors. No signiﬁcant differences were observed by using 1-way ANOVA with Dunnet's
post-comparison test.
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Figure 4. Anti-CD23 DARPins reduce IgE synthesis in an isotype-speciﬁc manner. IL-4 and anti-CD40 stimulated human B cells were cultivated with the
anti-CD23 DARPins D86, D89, or D89-86 or with the non-speciﬁc control DARPins (nsD and nsD-D) added at day 0. Cell supernatants were collected at
day 13 and IgE (A,B) and total IgG (D,E) levels were measured by ELISA. Because of high donor variability, the results for IgE were normalized to cultures
stimulated with IL-4 and anti-CD40 alone. The units represent the percentage of IgE secretion compared to the cultures stimulated with IL-4 and anti-
CD40 antibody alone (G) Germline andmature IgEmRNA transcripts were analyzed after 6 days of culture by real time RT-PCR. (F) IgG1 (n¼ 4) and IgG4
(n¼ 5) mRNA expression in na€ıve B cells was analyzed after 6 days of culture by real-time PCR (DDCt). Relative expression is shown as fold change
compared to anti-CD40/IL-4-stimulated samples (DDCt). Shown are means SEM, statistical signiﬁcance was calculated using 1-way ANOVA with
Dunnet's post-comparison test and considered signiﬁcant if P< 0.05.
M. Fellmann et al. High affinity targeting of CD23
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(Fig. 5A) and after 13 days (Fig. 5B) of culture, B cells were
stained with the apoptosis marker annexin V (Left panel)
or with the cell death marker 7-AAD (Right panel). Flow
cytometry demonstrated that the DARPin D89-86 did not
significantly enhance the percentage of apoptotic cells
compared to cells treated with IL-4 plus anti-CD40 alone
or in the presence of the control DARPin. As apoptosis can
be detected at earlier time points, cell viability was
investigated after 3 days but no significant reduction was
observed (data not shown).
Discussion
Previous studies have addressed the effect of targeting
CD23 using anti-CD23 antibodies or IgE-immune com-
plexes [11, 15]; however the importance of targeting CD23
per se has not been properly evaluated. In this study, we
used the DARPin technology to select binders that
recognize CD23 with exclusive specificity and with high
affinity. Two DARPins were selected that recognized two
different epitopes on CD23 and were able to interfere with
Figure 5. Anti-CD23 DARPins did not induce apoptosis in human B cells. Human B cells were cultivated with IL-4 and anti-CD40 alone or in the
presence of the bispeciﬁc anti-CD23 DARPin (D89-86) or the bispeciﬁc control DARPin (nsD-D) added at day 0. Cells were stained with 7-AAD and
FITC-conjugated Annexin V after 6 (A) and 13 days (B) and analyzed by ﬂow cytometry. Results are expressed as percent positive cells and are
means SEM of at least three donors.
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IgE binding on CD23. It has been shown that the binding
site of IgE on CD23 lies in the lectin ‘‘head’’ domain [3].
Therefore, we speculated that the epitopes recognized by
DARPins D89 and D86 are clearly distant from each other
but overlapped that of IgE. Genetically linking and
producing the DARPins D89 and D86 in a bispecific
format resulted in a molecule with an enhanced affinity in
the picomolar range and a stronger capacity to inhibit
binding of IgE to membrane CD23.
Our result showed that the bispecific DARPin D89-86
significantly enhanced CD23 surface expression and reduced
the amount of soluble CD23 released into the cell super-
natants. A similar effect has been observed with the natural
ligand, IgE, that increases cell surface expression by preventing
the release of soluble CD23 [26]. In contrast, monoclonal
anti-CD23 antibodies that bind to the lectin head domain
have been shown to decrease surface expression of CD23 by
inducing endocytosis [5]. However, like IgE and anti-CD23
antibodies, D89-86 did not alter expression of CD23 mRNA
levels of either CD23a or CD23b isoform. A likely explanation
is that bispecific DARPin D89-86 induces a conformational
change in CD23 that promotes oligomerization of CD23,
rendering it less susceptible to proteolysis. This has already
been observed by Gould et al. who suggested an allosteric
mechanism by which an anti-CD23 antibody recognizing the
lectin domain, or IgE, stabilizes membrane CD23 whereas
anti-CD23 antibodies which recognize the stalk region exert
the opposite effect [24, 27].
As mentioned, it has already been postulated that
binding CD23 on IgE secreting cells by IgE/anti-IgE
immune-complexes directly supresses IgE synthesis [15].
However, in that system it cannot be excluded that binding
of the anti-IgE antibody to membrane IgE mediates the IgE
suppression. Furthermore, studies using the chimeric anti-
CD23 antibody, lumiliximab, have claimed that the
reduced IgE synthesis requires co-aggregation with the
inhibitory Fcg-receptor [16]. Furthermore, it has been
reported that F(ab)2 of murine monoclonal anti-CD23
antibodies showed no or only marginal effects on in vitro
IL-4-induced IgE synthesis in peripheral blood lympho-
cytes [24]. In contrast to those studies, we showed that
targeting CD23 with D89-86 significantly reduced IgE
synthesis. This can be explained by the fact that upon
epitope specificity targeting CD23 may act differently on
IgE production as it has been described previously with
monoclonal antibodies recognizing distinct epitopes on
CD23 [28]. Furthermore, in contrast to F(ab)2 molecules
that recognize with both arms the same epitope, our
bispecific DARPin recognizes two epitopes leading to a
more efficient stabilization of CD23 on the cell surface.
This hypothesis is sustained by the fact that only the
bispecific DARPin D89-86, that efficiently stabilizes CD23
compared to the monovalent anti-CD23 DARPins,
reduced IgE synthesis. This result is in accordance with
the observation that protease inhibitors that block cleavage
of CD23 down-regulate IgE synthesis in vitro [8].
It was still unclear whether stabilization of CD23 on B cells
is associated with a reduced epsilon class switch recombina-
tion. Earlier work has shown that a monoclonal anti-CD23
antibody may have to cross-link with the FcgRIIb to block
germline Ce transcription [16]. Our results showed
decreased levels of the mature IgE transcript, whereas
epsilon germline transcript (eGLT) was not affected. It is
likely that binding of bispecific DARPin to CD23 does not
affect class switch at the stage of germline Ce transcription
but rather inhibits IgE synthesis after class-switch recombi-
nation (CSR) has occurred. Neither inhibition of IgG
synthesis nor decreased IgG1 and IgG4 mRNA levels upon
stimulation with bispecific DARPin were observed suggest-
ing an isotype-specific control for IgE synthesis through a
postswitch mechanism.
Additional experiments showed that targeting CD23 with
bispecific DARPin does not induce cell apoptosis but rather
induces a state of anergy as it has been postulated for the
humanized anti-human IgE antibody, omalizumab [29].
Induction of apoptosis in vitro might require extensive
cross-linking as it has been shown for the chimeric anti-
CD23 antibody, lumiliximab, by using a secondary antibody.
In vivo, such cross-linking most probably occurs through
binding of the Fc-domain to Fcg-receptors on NK cells or
other effector cells [14]. Whether extensive cross-linking by
increasing the valency of bispecific DARPin will lead to
apoptosis remains to be investigated.
Considering the suppressive effect of the bispecific
DARPin on IgE synthesis, we propose three possible
mechanisms. First, through its high affinity the bispecific
DARPin stabilizes CD23 and avoids the release of soluble
CD23 thereby preventing the positive effect of soluble CD23
on IgE synthesis. This view is supported by the fact that
bispecific DARPin enhances the surface expression of CD23
whereas monovalent DARPins, having lower affinities, were
less effective in reducing cleavage of CD23. Second, bispecific
DARPin D89-86 might deliver a negative signal through
cross-linking surface CD23 as it has been proposed with IgE-
immune-complexes [15]. At the cell surface, CD23 is
trimeric and analysis of the crystal structure of IgE bound
to CD23 has revealed a topology that does not allow IgE to
engage two lectin ‘‘head’’ domains within one CD23
molecule but might cross-link two membrane CD23
molecules [30]. Bispecific DARPin D89-86 contains a
flexible [Gly4-Ser]4 linker of approximately 7 nm whose
length does most likely not allow intramolecular cross-
linking of the CD23 ‘‘head’’ domains, but could cross-link
two membrane CD23 molecules. Although ITIM signaling
through CD23 is still not known, this may lead to a negative
signal through CD23. Third, the bispecific DARPin inhibits
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IgE synthesis by binding to and neutralizing soluble CD23.
The importance of soluble CD23 was reported by Gould
et al. demonstrating that soluble CD23 positively influences
IgE synthesis by cross-linking membrane IgE and CD21 [8].
Against this view is that monovalent DARPins, which can
bind to soluble CD23, have no inhibitory effect. This further
supports the hypothesis that bispecific DARPins are not
acting by preventing the binding of soluble CD23 but by
binding to membrane CD23.
In conclusion, we have demonstrated that targeting
CD23 with a high affinity bispecific DARPin is sufficient
to inhibit IgE production and does not require engage-
ment of an inhibitory Fcg-receptor. This effect was
mediated by a post switch mechanism that does not affect
eGLT. Furthermore, our data demonstrated the impor-
tance of high affinity binding to CD23 for stabilization
and revealed a remarkable relationship with down-
regulation of IgE synthesis. Additionally, we speculate
that bispecific DARPin has some capacity for signaling
but further studies are required to elucidate signal
transduction pathways.
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Figure S1. Epitope specificities of anti-CD23 DARPins. The
chip was saturated with bivalent DARPin D86-86, which has
a low off-rate dissociation constant.
Figure S2. Protein analysis of anti-CD23 DARPins. Anti-
CD23 DARPins (1.5mg) were visualized on a 15% SDS-
PAGE stained with Coomassie.
Figure S3. SPR sensorgrams for the assessment of binding
kinetics of anti-CD23 DARPins to CD23.
Figure S4. Expression of CD20 and CD23 on freshly isolated
B cells.
Figure S5. Effects of anti-CD23 DARPins on surface CD23
after 6 days of culture.
Figure S6. Effects of anti-CD23 DARPins on different
immunoglobulin isotypes.
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